celltrion healthcar co ltd -- -- -- -- -- -- -- -- -- -- -initi coverag under-perform
biolog product distributor celltrion group
biolog product local/region distributor europe/th us
 teva cthc share profit celltrion inc
proportion sell-out revenu per contract
cthc long-term goal start distribut celltrion biolog
product directli fact contract structur gradual evolv
co-market practic includ one teva
biosimilar shipment volum may remain weak near term
celltrion group experienc difficulti product
believ export momentum reviv
market cost burden continu
pressuris
earn given sequenti product launch europ
tp base blend dcf target price-to-earnings
methodolog mix attempt captur long-term
growth outlook near-term momentum valuat
demand given near-term weak cthc trade
averag discount celltrion inc seem fair
given lack capabl futur growth potenti
estimate pot chg tp
 chang prev ep
note celltrion healthcar conduct global market sale distribut biolog product
develop celltrion inc master distributorship agreement partnership region
click detail financi
distribut celltrion inc biolog product local/region distributor
europe/th us teva cthc direct ownership
celltrion inc share profit proportion sell-out
revenu per master distributorship agreement
shift direct distribut model upsid risk cthc
long-term goal start distribut celltrion biolog product
key market directli fact contract structur gradual evolv
co-market practic market includ one teva
contrariwis earli contract one ex-hospira
base
market sale activ
figur major global pfizer remsima eu
us teva truxima herzuma us
weak near-term momentum regardless market favour
celltrion biosimilar shipment volum may remain weak near term
celltrion group experienc difficulti product sinc
past year fda warn letter fill finish line issu seem
extend henc believ export
momentum reviv market cost burden
continu pressuris earn given sequenti product
launch europ truxima herzuma
initi under-perform rate find valuat
demand given near-term weak celltrion inc cthc
share busi profil oper valuat
close inter-link sinc list juli cthc trade
averag discount celltrion inc seem fair given
lack capabl futur growth potenti tp
base blend dcf target price-to-earnings methodolog mix
attempt captur long-term growth outlook near-term
momentum risk factor remain celltrion inc
acquisit global biopharma strengthen direct distribut
model could particular upsid risk cthc
figur celltrion hcconsensu valuat discount celltrion inc
bloomberg profession servic
seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid
report singl factor make invest decis
indexedindexedindex celltrion inc hc celltrion celltrion gp hc valuat discount celltrion incavg charl martineau pm univers toronto
compani mention price
ray certifi view express report accur reflect person view subject compani secur
part compens directli indirectli relat specif recommend view express report
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rela tive analyst coverag univers
consist compani cover analyst within relev sector outperform repres attractiv neutral less attract
underperform least attract invest opportun octob canadian well european rate base stock total return
rel analyst coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan
australia rate base stock total return rel averag total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti curren share price rel
attract stock total return potenti within analyst coverag univers australian new zealand stoc ks expect total return calcul
includ roll dividend yield outperform rate assign greater equal under-perform less
equal neutral may assign overlap rate rang allow analyst assign rate put
context associ risk prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat compani
time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view
equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat
sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within elev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral nd under-perform close correspond
